Bristol-Myers Squibb
In David Rolfe's portfolio · Wedgewood Partners
Ticker BMY
Not in the portfolio as of Q2 2026. Every quarter it shows up in a Wedgewood Partners 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q1 2023 | Sell | 0 | |
| Q4 2022 | Reduce 23% | 4,175 | 0.1% |
| Q3 2022 | Reduce 8% | 5,425 | 0.1% |
| Q2 2022 | Reduce 14% | 5,925 | 0.1% |
| Q1 2022 | Add 48% | 6,925 | 0.1% |
| Q4 2021 | Reduce 12% | 4,675 | 0.0% |
| Q3 2021 | Reduce 6% | 5,300 | 0.0% |
| Q2 2021 | Reduce 93% | 5,625 | 0.1% |
| Q1 2021 | Reduce 82% | 75,835 | 0.7% |
| Q1 2021 | Sell | 0 | |
| Q4 2020 | Reduce 6% | 414,057 | 3.8% |
| Q4 2020 | Reduce 7% | 122,750 | 0.0% |
| Q3 2020 | Add 18% | 439,319 | 4.2% |
| Q3 2020 | Reduce 2% | 131,557 | 0.0% |
| Q2 2020 | Add 44% | 373,781 | 3.7% |
| Q2 2020 | Reduce 10% | 134,729 | 0.1% |
| Q1 2020 | Reduce 34% | 259,180 | 2.7% |
| Q1 2020 | Buy | 148,901 | 0.1% |
| Q4 2019 | Buy | 391,442 | 2.5% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.